Antidepressant Drugs in Elderly

  • Cecilio Álamo
  • Francisco López-Muñoz
  • Pilar García-García


In our society, scientific advances and the improvement of the living conditions are causing a “demographic transition” with a significant increase in the number of elderly people. Antidepressant treatment in older depressed patients is efficacious, but differences in the effectiveness of different antidepressants have not been demonstrated. With ageing, a series of changes occur in the elderly that modify both the pharmacokinetics and pharmacodynamics of antidepressants and may influence the efficacy, tolerability and safety of treatment in the elderly. Individualized therapy for each elderly patient is needed to achieve acceptable risk–benefit ratio. ratiobebenefitratio.


Major Depressive Disorder Sexual Dysfunction Orthostatic Hypotension Antidepressant Drug Sexual Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gallagher P, Lang PO, Cherubini A, et al. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol. 2011;67:1175–88.CrossRefPubMedGoogle Scholar
  2. 2.
    Álamo C, López-Muñoz F, García-García P. Treatment of depression in elderly: the challenge to success. Int J Clin Psychiatry Ment Health. 2014;2:77–88.CrossRefGoogle Scholar
  3. 3.
    Álamo C, López-Muñoz F, García-García P, García-Ramos S. Risk–benefit analysis of antidepressant drug treatment in the elderly. Psychogeriatrics. 2014;14:261–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Wiese BS. Geriatric depression: the use of antidepressants in the elderly. BC Med J. 2011;53:341–7.Google Scholar
  5. 5.
    Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle age: a systematic review of comparative studies. Am J Psychiatry. 2005;162:1588–601.CrossRefPubMedGoogle Scholar
  6. 6.
    Cole MG, Bellavance F, Mansour A. Prognosis of depression in elderly community and primary care populations: a systematic review and meta-analysis. Am J Psychiatry. 1999;156:1182–9.PubMedGoogle Scholar
  7. 7.
    Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging. 2009;26:381–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Álamo C, López-Muñoz F. New antidepressant drugs: beyond monoaminergic mechanisms. Curr Pharm Des. 2009;15:1559–62.CrossRefPubMedGoogle Scholar
  9. 9.
    López-Muñoz F, Álamo C. Neurobioloy of monoaminergic neurotransmission and antidepressants. In: Srinivasan V, Brzezinski A, Oter S, Shillcutt SD, editors. Melatonin and melatonergic drugs in clinical practice. New Delhi: Springer International; 2014. p. 321–41.CrossRefGoogle Scholar
  10. 10.
    Zhang H, Etherington LA, Hafner AS, et al. Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule. Mol Psychiatry. 2013;18:471–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Invernizzi R, Pozzi L, Garattini S, Samanin R. Tianeptine increases the extracellular concentrations of dopamine in the nucleus accumbens by a serotonin-independent mechanism. Neuropharmacology. 1992;31:221–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Álamo C, López-Muñoz F, García-García P. Influencia de los antidepresivos en la salud física del paciente deprimido. In: Bobes J, Giner J, López F, Saiz-Ruiz J, Zamorano E, editors. Salud Física en el Paciente con Depresión. Madrid: Fundación Española de Psiquiatría y Salud Mental; 2012. p. 281–365.Google Scholar
  13. 13.
    Fangmann P, Assion H, Juckel G, et al. Half a century of antidepressant drugs on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics. J Clin Psychopharmacol. 2008;28:1–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Calati R, Signorelli MS, Balestri M, et al. Antidepressants in elderly: metaregression of double-blind, randomized clinical trials. J Affect Disord. 2013;147:1–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Álamo C. Polifarmacia y fragilidad. Interacciones, reacciones adversas medicamentosas y seguridad de los fármacos. En: Guía de Buena Práctica Clínica en Geriatría. Fragilidad y nutrición en el anciano. Madrid: Sociedad Española de Geriatría y Gerontología; 2014.Google Scholar
  16. 16.
    American Geriatrics Society. Beers criteria update expert panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616–31.CrossRefGoogle Scholar
  17. 17.
    Gerson SC, Plotkin DA, Jarvik LF. Antidepressant drug studies, 1964 to 1986: empirical evidence for aging patients. J Clin Psychopharmacol. 1988;8:311–22.CrossRefPubMedGoogle Scholar
  18. 18.
    Cleare A, Pariante CM, Young AH, et al. Members of the Consensus Meeting. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015;29:459–525.Google Scholar
  19. 19.
    Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. Clin Ther. 2009;31:945–61.CrossRefPubMedGoogle Scholar
  20. 20.
    Tedeschini E, Levkovitz Y, Iovieno N, et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72:1660–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord. 2012;141:103–15.CrossRefPubMedGoogle Scholar
  22. 22.
    National Institute of Health and Clinical Excellence (NICE). Clinical Guideline 23. The management of depression in primary and secondary care. 2004.Google Scholar
  23. 23.
    Wilkinson P, Izmeth Z. Continuation and maintenance treatments for depression in older people. Cochrane Database Syst Rev. 2012;(11):CD006727. doi: 10.1002/14651858.CD006727.pub2.
  24. 24.
    Andreescu C, Reynolds CF. Depresión a una edad avanzada: tratamiento basado en la evidencia y nuevos caminos prometedores para la investigación y la práctica clínica. Psiquatr Biol. 2012;19:116–26.Google Scholar
  25. 25.
    Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother. 2014;15:2525–42.CrossRefPubMedGoogle Scholar
  26. 26.
    Chua HC, Chan LL, Chee KS, et al. Ministry of health clinical practice. Guidelines: depression. Singap Med J. 2012;53:137–44.Google Scholar
  27. 27.
    Álamo C, López-Muñoz F, Guerra JA. Psicofarmacología en Neuropsicogeriatría. In: Gil Gregorio P, editor. Tratado de Neuropsicogeriatría. Madrid: Ergon; 2010. p. 27–58.Google Scholar
  28. 28.
    Tan RS. Dose of tricyclic antidepressants in elderly patients. JAMA. 1999;281:1891–2.CrossRefPubMedGoogle Scholar
  29. 29.
    Volz HP, Gleiter CH. Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998;13:341–55.CrossRefPubMedGoogle Scholar
  30. 30.
    Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62:792–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry. 2003;64:5–12.CrossRefPubMedGoogle Scholar
  32. 32.
    Lichtman JH, Bigger Jr JT, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American heart association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research: endorsed by the American psychiatric association. Circulation. 2008;118:1768–75.CrossRefPubMedGoogle Scholar
  33. 33.
    Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108:2–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Blanchette CM, Simoni-Wastila L, Zuckerman IH, Stuart B. A secondary analysis of a duration response association between selective serotonin reuptake inhibitor use and the risk of acute myocardial infarction in the aging population. Ann Epidemiol. 2008;18:316–21.CrossRefPubMedGoogle Scholar
  35. 35.
    Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108:32–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Undela K, Parthasarathi G, John SS. Impact of antidepressants use on risk of myocardial infarction: a systematic review and meta-analysis. Indian J Pharmacol. 2015;47:256–62.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005;91:465–71.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    National Collaborating Centre for Mental Health, commissioned by NICE. Depression in adults with a chronic physical health problem: treatment and management. National Clinical Practice Guideline 91. 2009.Google Scholar
  41. 41.
    National Health Service. UK Medicines Information. What is the antidepressant of choice in coronary heart disease? UKMi Q&A 55.6, 2012.Google Scholar
  42. 42.
    Van der Kooy K, van Hout H, Marwijk H, et al. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int J Geriatr Psychiatry. 2007;22:613–26.CrossRefPubMedGoogle Scholar
  43. 43.
    Hackett ML, Anderson CS, House AO. Management of depression after stroke. A systematic review of pharmacological therapies. Stroke. 2005;36:1092–7.CrossRefGoogle Scholar
  44. 44.
    Chen Y, Guo JJ. Meta-analysis of antidepressant treatment for patients with poststroke depression. Stroke. 2006;37:1365–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Chen Y, Guo JJ, Zhan S, Patel NC. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother. 2006;40:2115–22.CrossRefPubMedGoogle Scholar
  46. 46.
    Chen Y, Patel NC, Guo JJ, Zhan S. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007;22:159–66.CrossRefPubMedGoogle Scholar
  47. 47.
    Chen Y, Guo JJ, Li H, et al. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case-control study. Ann Pharmacother. 2008;42:177–84.CrossRefPubMedGoogle Scholar
  48. 48.
    Wu CS, Wang SC, Cheng YC, Gau SS. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry. 2011;168:511–21.CrossRefPubMedGoogle Scholar
  49. 49.
    Péquignot R, Tzourio C, Péres K, et al. Depressive symptoms, antidepressants and disability and future coronary heart disease and stroke events in older adults: the Three City Study. Eur J Epidemiol. 2013;28:249–56.CrossRefPubMedGoogle Scholar
  50. 50.
    Pan A, Sun Q, Okereke OI, et al. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA. 2011;306:1241–9.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Trifiro G, Dieleman J, Sen EF, et al. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. J Clin Psychopharmacol. 2010;30:252–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Lee YC, Lin CH, Lin MS, et al. Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study. J Clin Psychopharmacol. 2013;33:782–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Juang HT, Chen PC, Chien KL. Using antidepressants and the risk of stroke recurrence: report from a national representative cohort study. BMC Neurol. 2015;15:86.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Wang MT, Chu CL, Yeh CB, et al. Antidepressant use and risk of recurrent stroke: a population-based nested case-control study. J Clin Psychiatry. 2015;76:e877–85.CrossRefPubMedGoogle Scholar
  55. 55.
    Kharofa J, Sekar P, Haverbusch M, et al. Selective serotonin Reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007;38:3049–51.CrossRefPubMedGoogle Scholar
  56. 56.
    Douglas I, Smeeth L, Irvine D. The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study. Br J Clin Pharmacol. 2011;71:116–20.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Aarts N, Akoudad S, Noordam R, et al. Inhibition of serotonin reuptake by antidepressants and cerebral microbleeds in the general population. Stroke. 2014;45:1951–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012;79:1862–5.CrossRefPubMedGoogle Scholar
  59. 59.
    Mikami K, Jorge RE, Adams HP, et al. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry. 2011;19:1007–15.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Chollet F, Tardy J, Albucher J-F, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10:123–30.CrossRefPubMedGoogle Scholar
  61. 61.
    Mead GE, Hsieh C-F, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012;11:CD009286.PubMedGoogle Scholar
  62. 62.
    Mead G, Hackett ML, Lundström E, et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. Trials. 2015;16:369.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Mago R, Tripathi N, Andrade C. Cardiovascular adverse effects of newer antidepressants. Expert Rev Neurother. 2014;14:539–51.CrossRefPubMedGoogle Scholar
  64. 64.
    Davies EA, O’Mahonny MS. Adverse drug reactions in special populations – the elderly. Br J Clin Pharmacol. 2015;80:796–807.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Mitchell J, Trangle M, Degnan B, et al. Health care guideline: adult depression in primary care guideline [Internet]. Bloomington: Institute for Clinical Systems Improvement; 2013. Available at: Scholar
  66. 66.
    Licht CM, De Geus EJ, Seldenrijk A, et al. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension. 2009;53:631–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Derby MA, Zhang L, Chappell JC, et al. The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol. 2007;49:384–93.CrossRefPubMedGoogle Scholar
  68. 68.
    Mclntyre RS, Park Y, Law CW, et al. The association between conventional antidepressants and the metabolic syndrome a review of the evidence and clinical implications. CNS Drugs. 2010;24:741–63.CrossRefGoogle Scholar
  69. 69.
    Van der Kooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry. 2002;47:174–80.Google Scholar
  70. 70.
    Martín-Agueda B, López-Muñoz F, Rubio G, et al. Management of depression in primary care: a survey of general practitioners in Spain. Gen Hosp Psychiatr. 2005;27:305–12.CrossRefGoogle Scholar
  71. 71.
    Magnuson T, Keller BK. Treatment for geriatric depression. The Nebraska Geriatrics Education Center, 2009. Available at:
  72. 72.
    Fanoe S, Kristensen D, Fink-Jensen A, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. Eur Heart J. 2014;35:1306–15.CrossRefPubMedGoogle Scholar
  73. 73.
    Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004;45:371–7.CrossRefPubMedGoogle Scholar
  74. 74.
    Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Thase ME, Larsen KG, Reines E, et al. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23:1391–400.CrossRefPubMedGoogle Scholar
  76. 76.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–9.CrossRefPubMedGoogle Scholar
  77. 77.
    Pan A, Sun Q, Okereke OI, et al. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia. 2012;55:63–72.CrossRefPubMedGoogle Scholar
  78. 78.
    Ludman EJ, Katon W, Russo J, et al. Depression and diabetes symptom burden. Gen Hosp Psychiatry. 2004;26:430–6.CrossRefPubMedGoogle Scholar
  79. 79.
    Azevedo Da Silva M, Dugravot A, Balkau B, et al. D.E.S.I.R. Study Group. Antidepressant medication use and trajectories of fasting plasma glucose, glycated haemoglobin, β-cell function and insulin sensitivity: a 9-year longitudinal study of the D.E.S.I.R. cohort. Int J Epidemiol 2015. pii: dyv153.Google Scholar
  80. 80.
    Kivimäki M, Hamer M, Batty GD, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care. 2010;33:2611–6.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Khoza S, Barner JC, Bohman TM, et al. Use of antidepressant agents and the risk of type 2 diabetes. Eur J Clin Pharmacol. 2012;68:1295–302.CrossRefPubMedGoogle Scholar
  82. 82.
    Derijks HJ, Meyboom RH, Heerdink ER, et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol. 2008;64:531–8.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Boyer P, Montgomery S, Lepóla U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo controlled trial. Int Clin Psychopharmacol. 2008;23:243–53.CrossRefPubMedGoogle Scholar
  84. 84.
    Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med. 2007;8:503–13.CrossRefPubMedGoogle Scholar
  85. 85.
    Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care. 2006;29:170–1.CrossRefPubMedGoogle Scholar
  86. 86.
    Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591–8.CrossRefPubMedGoogle Scholar
  87. 87.
    Markowitz S, Gonzalez JS, Wilkinson JL, Safren SA. Treating depression in diabetes emerging findings. Psychosomatics. 2011;52:1–18.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Van Reedt Dortland AK, Giltay EJ, van Veen T, et al. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand. 2010;122:30–9.CrossRefPubMedGoogle Scholar
  89. 89.
    Mclntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Exp Opin Drug Saf. 2006;5:523–37.CrossRefGoogle Scholar
  90. 90.
    Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry. 2003;64:883–9.CrossRefPubMedGoogle Scholar
  91. 91.
    Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs. placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62:190–8.CrossRefPubMedGoogle Scholar
  92. 92.
    Le Melledo JM, Mailo K, Lara N, et al. Paroxetine-induced increase in LDL cholesterol levels. J Psychopharmacol. 2009;23:826–30.CrossRefPubMedGoogle Scholar
  93. 93.
    Bostwick JM. A generalist’s guide to treating patients with depression. With an emphasis on using side effects to tailor antidepressant therapy. Mayo Clin Proc. 2010;85:538–50.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Fava M. Weight gain and antidepressants. J Clin Psychiatr. 2000;61 Suppl 11:37–41.Google Scholar
  95. 95.
    Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry. 2001;62:256–60.CrossRefPubMedGoogle Scholar
  96. 96.
    Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther. 2002;24:662–72.CrossRefPubMedGoogle Scholar
  97. 97.
    Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs. 2010;24:479–99.CrossRefPubMedGoogle Scholar
  98. 98.
    Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. Maturitas. 2013;76:357–63.CrossRefPubMedGoogle Scholar
  99. 99.
    Spigset O, Hedenmalm K. Hyponatraemia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by psychotropic drugs. Drug Saf. 1995;12:209–25.CrossRefPubMedGoogle Scholar
  100. 100.
    Niranjan K, Nasim A. Hyponatraemia: removing the risk in the elderly. Geriatr Med. 2005;35:17–21.Google Scholar
  101. 101.
    Bouman WP, Pinner G, Johnson H. Incidence of selective serotonin-reuptake inhibitor (SSRI)-induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry. 1998;13:12–5.CrossRefPubMedGoogle Scholar
  102. 102.
    Ayus JC, Arrief AI. Chronic hyponatremic encephalopathy in postmenopausal women. JAMA. 1999;281:2299–304.CrossRefPubMedGoogle Scholar
  103. 103.
    Sultana J, Spina E, Trifirò G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol. 2015;11:883–92.CrossRefPubMedGoogle Scholar
  104. 104.
    De Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake-inhibitors and upper gastrointestinal bleeding: population-based, case–control study. BMJ. 1999;319:1106–9.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323:655–8.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    De Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. 2011;28:345–67.CrossRefPubMedGoogle Scholar
  107. 107.
    Ghio L, Puppo S, Presta A. Venlafaxine and risk of upper gastrointestinal bleeding in elderly depression. Curr Drug Saf. 2012;7:389–90.CrossRefPubMedGoogle Scholar
  108. 108.
    Shin JY, Park MJ, Lee SH, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ. 2015;351:h3517.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Barbui C, Andretta M, De Vitis G, et al. Antidepressant drug prescription and risk of abnormal bleeding: a case-control study. J Clin Psychopharmacol. 2009;29:33–8.CrossRefPubMedGoogle Scholar
  110. 110.
    Mahdanian AA, Rej S, Bacon SL, et al. Serotonergic antidepressants and perioperative bleeding risk: a systematic review. Expert Opin Drug Saf. 2014;13:695–704.PubMedGoogle Scholar
  111. 111.
    Aloumanis K, Mavroudis K. The “depressive” face of osteoporosis and the “osteoporotic” face of depression. Hormones (Athens). 2013;12:350–62.Google Scholar
  112. 112.
    Bruyère O, Reginster JY. Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine. 2015;48:65–8.CrossRefPubMedGoogle Scholar
  113. 113.
    Cizza G, Primma S, Coyle M, Gourgiotis L, Csako G. Depression and osteoporosis: a research synthesis with meta-analysis. Horm Metab Res. 2010;42:467–82.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. Bone. 2012;51:606–13.CrossRefPubMedGoogle Scholar
  115. 115.
    Sansone RA, Sansone LA. SSRIs: bad to the bone? Innov Clin Neurosci. 2012;9:42–7.Google Scholar
  116. 116.
    Verdel BM, Souverein PC, Egberts TC, et al. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone. 2010;47:604–9.CrossRefPubMedGoogle Scholar
  117. 117.
    Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos Int. 2013;24:121–37.CrossRefPubMedGoogle Scholar
  118. 118.
    Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos Int. 2014;25:1473–81.CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Reichenpfader U, Gartlehner G, Morgan LC, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf. 2014;37:19–31.CrossRefPubMedGoogle Scholar
  120. 120.
    Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol. 2010;24:111–20.CrossRefPubMedGoogle Scholar
  121. 121.
    Pae CU. Agomelatine: a new option for treatment of depression? Exp Opin Pharmacother. 2014;15:443–7.CrossRefGoogle Scholar
  122. 122.
    Schweitzer I, Maguire K. Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry. 2009;43:795–808.CrossRefPubMedGoogle Scholar
  123. 123.
    Schulz R, Drayer RA, Rollman BL. Depression as a risk factor for non-suicide mortality in the elderly. Biol Psychiatry. 2002;52:205–25.CrossRefPubMedGoogle Scholar
  124. 124.
    Bogner HR, Morales KH, Reynolds CF, et al. Course of depression and mortality among older primary care patients. Am J Geriatr Psychiatry. 2012;20:895–903.CrossRefPubMedPubMedCentralGoogle Scholar
  125. 125.
    Gallo JJ, Morales KH, Bogner HR, et al. Long term effect of depression care management on mortality in older adults: follow-up of cluster randomized clinical trial in primary care. BMJ. 2013;346:f2570.CrossRefPubMedPubMedCentralGoogle Scholar
  126. 126.
    Gallo JJ, Hwang S, Joo JH, et al. Multimorbidity, depression, and mortality in primary care: randomized clinical trial of an evidence-based depression care management program on mortality risk. J Gen Intern Med. 2016;31:380–6.CrossRefPubMedGoogle Scholar
  127. 127.
    Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–74.CrossRefPubMedGoogle Scholar
  128. 128.
    Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42:277–85.CrossRefPubMedGoogle Scholar
  129. 129.
    Bremner JD, Wingard P, Walshe TA. Safety of mirtazapine in overdose. J Clin Psychiatry. 1998;59:233–5.CrossRefPubMedGoogle Scholar
  130. 130.
    Crumpacker DW. Suicidality and antidepressants in the elderly. Proc Bayl Univ Med Cent. 2008;21:373–7.PubMedPubMedCentralGoogle Scholar
  131. 131.
    Gusmão R, Quintão S, McDaid D, et al. Antidepressant utilization and suicide in Europe: an ecological multi-national study. PLoS ONE. 2013;8:e66455.CrossRefPubMedPubMedCentralGoogle Scholar
  132. 132.
    Leon AC, Solomon DA, Li C, et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry. 2011;72:580–6.CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Barak Y, Olmer A, Aizenberg D. Antidepressants reduce the risk of suicide among elderly depressed patients. Neuropsychopharmacology. 2006;31:178–81.PubMedGoogle Scholar
  134. 134.
    Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.CrossRefPubMedPubMedCentralGoogle Scholar
  135. 135.
    Frank C. Pharmacologic treatment of depression in the elderly. Can Fam Physician. 2014;60:121–6.PubMedPubMedCentralGoogle Scholar
  136. 136.
    Urban M, Navratil T, Pelclova D. Trends in CNS affecting drugs in the calls to t the Toxicological Information Center from 1997 to 2012. Neuro Endocrinol Lett. 2013;34:S25–30.Google Scholar
  137. 137.
    Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30:1206–27.CrossRefPubMedGoogle Scholar
  138. 138.
    Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • Cecilio Álamo
    • 1
  • Francisco López-Muñoz
    • 2
    • 3
    • 4
  • Pilar García-García
    • 1
  1. 1.Department of Biomedical Sciences (Pharmacology Area), Faculty of Medicine and Health SciencesUniversity of AlcaláAlcalá de Henares, MadridSpain
  2. 2.Faculty of Health SciencesCamilo José Cela UniversityMadridSpain
  3. 3.Neuropsychopharmacology UnitHospital 12 de Octubre Research Institute (i+12)MadridSpain
  4. 4.Portucalense Institute of Neuropsychology and Cognitive and Behavioural NeurosciencesPortucalense UniversityPortoPortugal

Personalised recommendations